Generalized Pustular Psoriasis (GPP) Market
Generalized Pustular Psoriasis (GPP) Market - Global Industry Assessment & Forecast
#
Pages:
215
Base Year:
2023
Nov - 2024
Format:
Report Code:
VMR-3179
Segments Covered
By
Treatment Topical Agents, Non-biologic agents, Biologic agents, TNFa antagonists, Antibiotics, Others
-
By
Route of Administration Oral, Topical, Subcutaneous, Other
-
By
End User Hospitals, Dermatology Clinics, Specialty Centers, Others
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 18.3 Billion |
 Revenue 2032:
|
USD 31.73 Billion |
 Revenue CAGR
(2024 - 2032): |
6.3% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Generalized Pustular Psoriasis (GPP) Market Segment Analysis
- Generalized Pustular Psoriasis (GPP) Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Generalized Pustular Psoriasis (GPP) Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Topical
- Subcutaneous
- Other
- Generalized Pustular Psoriasis (GPP) End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
-
North America Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
-
North America Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- U.S.
- U.S. Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- U.S. Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- U.S. Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- U.S. Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Canada
- Canada Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Canada Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Canada Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Canada Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Mexico
- Mexico Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Mexico Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Mexico Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Mexico Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
North America Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Europe
-
Europe Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
-
Europe Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
-
Europe Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- U. K.
- U.K. Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- U.K. Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- U.K. Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- U.K. Generalized Pustular Psoriasis (GPP) Market, by Treatment
- France
- France Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- France Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- France Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- France Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Germany
- Germany Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Germany Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Germany Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Germany Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Italy
- Italy Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Italy Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Italy Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Italy Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Spain
- Spain Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Spain Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Spain Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Spain Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Rest of Europe
- Rest of Europe Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Rest of Europe Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Rest of Europe Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Rest of Europe Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Europe Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Asia Pacific
-
Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
-
Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
-
Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- China
- China Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- China Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- China Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- China Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Japan
- Japan Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Japan Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Japan Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Japan Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Germany
- Germany Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Germany Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Germany Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Germany Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
India
- India Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- India Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- India Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- India Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
South Korea
- South Korea Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- South Korea Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- South Korea Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- South Korea Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
South East Asia
- South East Asia Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- South East Asia Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- South East Asia Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- South East Asia Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Rest of Asia Pacific
- Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Latin America
-
Latin America Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
-
Latin America Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
-
Latin America Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Brazil
- Brazil Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Brazil Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Brazil Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Brazil Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Argentina
- Argentina Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Argentina Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Argentina Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Argentina Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Rest of Latin America
- Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Latin America Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Middle East & Africa
-
Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
-
Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
-
Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- GCC Countries
- GCC Countries Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- GCC Countries Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- GCC Countries Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- GCC Countries Generalized Pustular Psoriasis (GPP) Market, by Treatment
- South Africa
- South Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- South Africa Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- South Africa Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- South Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
- Topical Agents
- Non-biologic agents
- Biologic agents
- TNFa antagonists
- Antibiotics
- Others
- Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
- Oral
- Topical
- Subcutaneous
- Other
- Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by End User
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Others
- Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
-
Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
- North America
FAQ
Frequently Asked Question
What is the global demand for Generalized Pustular Psoriasis (GPP) in terms of revenue?
-
The global Generalized Pustular Psoriasis (GPP) valued at USD 18.3 Billion in 2023 and is expected to reach USD 31.73 Billion in 2032 growing at a CAGR of 6.3%.
Which are the prominent players in the market?
-
The prominent players in the market are Eli Lilly and Company, Amgen Inc., Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, UCB Inc., Pfizer Inc., AbbVie Inc., Novartis AG, Astellas Pharma Inc..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.3% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Generalized Pustular Psoriasis (GPP) include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Generalized Pustular Psoriasis (GPP) in 2023.
